{"id":"dsxs","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, DSXS reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"DSXS is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:04.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02618759","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-08-28","conditions":"Plaque Psoriasis","enrollment":119},{"nctId":"NCT02933502","phase":"PHASE2","title":"Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-07-11","conditions":"Scalp Psoriasis","enrollment":3},{"nctId":"NCT02595073","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-09-04","conditions":"Atopic Dermatitis","enrollment":124},{"nctId":"NCT02932891","phase":"PHASE2","title":"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-08","conditions":"Atopic Dermatitis","enrollment":28},{"nctId":"NCT02601469","phase":"PHASE2","title":"Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-09-04","conditions":"Plaque Psoriasis","enrollment":26},{"nctId":"NCT02595008","phase":"PHASE2","title":"Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-08-28","conditions":"Dermatitis, Atopic","enrollment":24},{"nctId":"NCT02932462","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-03","conditions":"Scalp Psoriasis","enrollment":373},{"nctId":"NCT02413229","phase":"PHASE2","title":"A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-04","conditions":"Plaque Psoriasis","enrollment":151},{"nctId":"NCT02933866","phase":"PHASE3","title":"Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-03-11","conditions":"Scalp Psoriasis","enrollment":371},{"nctId":"NCT02933528","phase":"PHASE2","title":"Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-07-11","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT02932878","phase":"PHASE2","title":"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-09-02","conditions":"Plaque Psoriasis","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Active","DSXS 1535"],"phase":"phase_3","status":"active","brandName":"DSXS","genericName":"DSXS","companyName":"Sun Pharmaceutical Industries, Inc.","companyId":"sun-pharmaceutical-industries-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DSXS is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}